In Review: Last week, Lucia Lebens, PCMA’s Chief Government Affairs Officer, participated in a panel discussion at the 2025 Healthcare Transformation Summit on Thursday, November 6.
The panel focused on Navigating Federal Health Reforms: From Most Favored Nation to Market Disruption & The Big Beautiful Bill.
It was a busy week on the legislative front.
- SB 207– relating to copay accumulators – had an opposition hearing on November 4. PCMA testified in opposition.
- SB 160 – relating to frozen formulary. The author of the bill is open to amending the bill. PCMA suggested language to the bill, including freezing the price of the drugs for the year, as well as some transparency measures. The author of the bill is currently contemplating some of PCMA’s suggestions.
- HB 229 – relating to PBM licensure, had a proponent hearing on November 4.
- HB 192 – relating to minimum reimbursements, decline to dispense, prohibit retaliation, specialty drug labeling prohibitions, had a hearing on November 4 at 9:30 A.M. An amendment was introduced at the request of BlinkRx. You can view this amendment by clicking here.
Finally, at the request of Representative Kellie Deeter (R), PCMA met with BlinkRx. BlinkRx wanted to introduce an amendment that would allow enrollees and pharmacies to provide information to a third-party entity as it relates to pricing and transparency. PCMA is continuing to learn more about BlinkRx and better understand their legislative intent.
If you have any questions, please contact Sean Stephenson at sstephenson@pcmanet.org.
